Please login to the form below

Not currently logged in
Email:
Password:

Actavis Germany H1 2007 sales increase 21 per cent

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

With Actavis' third party division sales included in the results, total sales in Germany were EUR 66m in H1 FY07. Actavis' largest market is North America, which brought in sales of over EUR 500m in annual sales.

IMS data has also revealed that Actavis Deutschland is the seventh largest generic pharmaceuticals company in Germany, which is also Europe's largest generics market.

Even though market reforms and generic price erosion have reduced the attractiveness of the German market, Actavis has still increased its revenue growth in the region by 21 per cent, compared with H1 FY06 figures. The success has been attributed to Actavis' full product pipeline and sales force of 130 reps, which is set to increase.

The recent preferred partnership contract agreement with Allgemeine Ortskrankenkassen (AOK), Germany's largest General local health insurance provider, has helped ramp up sales. Actavis also provides over 40 products for the VdAK and the AEV insurance associations.

Actavis' deputy CEO, Sigurdur Oli Olafsson, said: "Going forward, we expect to see good growth in our German business, through an increasing number of new product launches, continued alliances with leading German insurance funds, as well as our important partnership arrangements with German generic companies for product supply."

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics